This video is sponsored by the Duke Clinical Medical Series.
Topics include:
* Cardiogenic Shock (CS) in 2005: The Value of IABP
* Case Presentation
* CS in 2005
* Temporal Trends in CS NRMI-2 Experience
* Survival
* SHOCK Trial: Survival
* CS: Timing of Procedures
* Revascularization Trends in CS: NRMI 1994 2004
* In-hospital Mortality in CS: NRMI 1994 2004
* Reduction in Mortality with PCI in CS: NRMI 1994 2004
The moderator, Peter Berger, MD, has indicated that he receives research/grant support
from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an
advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific
symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also
serves as Medical Director and has equity with Lumen, Inc.
The guest faculty, magnus Ohman, MB, ChB, has indicated that he receives research/grant
support from Berlex, Millenium, Schering-Plough. Dr. Ohman is also a consultant for
Bristol-Myers Squibb, Sanofi-aventis, Datascope, LipoScience.
|
|